Literature DB >> 2452484

Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides.

G H Lowell1, W R Ballou, L F Smith, R A Wirtz, W D Zollinger, W T Hockmeyer.   

Abstract

Proteosomes are hydrophobic, membranous, multimolecular preparations of meningococcal outer membrane proteins that are also B cell mitogens. These characteristics suggested that proteosomes may serve as carrier proteins and adjuvants to enhance peptide immunogenicity. Although high titers of malaria circumsporozoite (CS) antibodies protect against malaria, vaccines thus far tested in humans have been insufficiently immunogenic to be clinically useful. Here it is shown that synthetic CS peptides hydrophobically complexed to proteosomes by way of lauroyl-cysteine become highly immunogenic in mice without other adjuvants. The high titers of antibodies produced and the safety of proteosomes in humans suggest that this novel system is widely applicable for the development of peptide vaccines to protect against many diseases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452484     DOI: 10.1126/science.2452484

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  27 in total

1.  Neisseria meningitidis lipopolysaccharide modulates the specific humoral immune response to neisserial porins but has no effect on porin-induced upregulation of costimulatory ligand B7-2.

Authors:  N Bhasin; Y Ho; L M Wetzler
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.

Authors:  Delia F Tifrea; Sukumar Pal; Deana N Toussi; Paola Massari; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-08-30       Impact factor: 2.700

3.  Delivery of foreign antigens by engineered outer membrane vesicle vaccines.

Authors:  David J Chen; Nikolaus Osterrieder; Stephan M Metzger; Elizabeth Buckles; Anne M Doody; Matthew P DeLisa; David Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-27       Impact factor: 11.205

4.  Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.

Authors:  G H Lowell; C Colleton; D Frost; R W Kaminski; M Hughes; J Hatch; C Hooper; J Estep; L Pitt; M Topper; R E Hunt; W Baker; W B Baze
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 5.  Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity.

Authors:  Lee M Wetzler
Journal:  Future Microbiol       Date:  2010-05       Impact factor: 3.165

6.  Neisserial porins may provide critical second signals to polysaccharide-activated murine B cells for induction of immunoglobulin secretion.

Authors:  C M Snapper; F R Rosas; M R Kehry; J J Mond; L M Wetzler
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

7.  A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.

Authors:  R W Tindle; S Croft; K Herd; K Malcolm; A F Geczy; T Stewart; G J Fernando
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

8.  Role of protein tyrosine kinase and Erk1/2 activities in the Toll-like receptor 2-induced cellular activation of murine B cells by neisserial porin.

Authors:  Heather MacLeod; Navneet Bhasin; Lee M Wetzler
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

9.  Engineering the cell surface display of cohesins for assembly of cellulosome-inspired enzyme complexes on Lactococcus lactis.

Authors:  Andrew S Wieczorek; Vincent J J Martin
Journal:  Microb Cell Fact       Date:  2010-09-14       Impact factor: 5.328

10.  Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.

Authors:  R Glück; R Mischler; S Brantschen; M Just; B Althaus; S J Cryz
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.